Therefore, to save foreign exchange costs, reduce the treatment costs of breast cancer, and due to the cost-effectiveness of the two similar drugs manufactured by Homa Pharmed Company, the use of the Iranian GnRH agonist is recommended. This evidence concerns the gene GNRH1 and breast cancer.